Tìm theo
Ciprofloxacin
Các tên gọi khác (11 ) :
  • 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
  • 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
  • 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
  • 1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid
  • 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
  • 1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
  • 1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
  • Ciprofloxacin
  • Ciprofloxacine
  • Ciprofloxacino
  • Ciprofloxacinum
Thuốc dùng điều trị mắt, tai mũi họng
Thuốc Gốc
Small Molecule
CAS: 85721-33-1
ATC: S01AE03, J01MA02, S03AA07, S02AA15
ĐG : ACS Dobfar SPA , http://www.acsdobfar.it
CTHH: C17H18FN3O3
PTK: 331.3415
A broad-spectrum antimicrobial carboxyfluoroquinoline. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C17H18FN3O3
Phân tử khối
331.3415
Monoisotopic mass
331.133219662
InChI
InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
InChI Key
InChIKey=MYSWGUAQZAJSOK-UHFFFAOYSA-N
IUPAC Name
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
Traditional IUPAC Name
ciprofloxacin
SMILES
OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O
Độ tan chảy
255-257 °C
Độ hòa tan
3E+004 mg/L (at 20 °C)
logP
0.28
logS
-2.4
pKa (strongest acidic)
5.76
pKa (Strongest Basic)
8.68
PSA
72.88 Å2
Refractivity
87.94 m3·mol-1
Polarizability
33.12 Å3
Rotatable Bond Count
3
H Bond Acceptor Count
6
H Bond Donor Count
2
Physiological Charge
0
Number of Rings
4
Bioavailability
1
Rule of Five
true
pKa
6.09
Dược Lực Học : Ciprofloxacin is a broad-spectrum antiinfective agent of the fluoroquinolone class. Ciprofloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. The mechanism of action of quinolones, including ciprofloxacin, is different from that of other antimicrobial agents such as beta-lactams, macrolides, tetracyclines, or aminoglycosides; therefore, organisms resistant to these drugs may be susceptible to ciprofloxacin. There is no known cross-resistance between ciprofloxacin and other classes of antimicrobials. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian.
Cơ Chế Tác Dụng : A broad-spectrum antimicrobial carboxyfluoroquinoline. [PubChem] The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, strand supercoiling repair, and recombination.
Dược Động Học :
▧ Absorption :
Rapidly and well absorbed from the gastrointestinal tract after oral administration. The absolute bioavailability is approximately 70% with no substantial loss by first pass metabolism.
▧ Protein binding :
20 to 40%
▧ Metabolism :
Hepatic. Four metabolites have been identified in human urine which together account for approximately 15% of an oral dose. The metabolites have antimicrobial activity, but are less active than unchanged ciprofloxacin.
▧ Route of Elimination :
Approximately 40 to 50% of an orally administered dose is excreted in the urine as unchanged drug.
▧ Half Life :
4 hours
▧ Clearance :
* Renal cl=300 mL/min
Độc Tính : The major adverse effect seen with use of is gastrointestinal irritation, common with many antibiotics.
Chỉ Định : For the treatment of the following infections caused by susceptible organisms: urinary tract infections, acute uncomplicated cystitis, chronic bacterial prostatitis, lower respiratory tract infections, acute sinusitis, skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections (used in combination with metronidazole), infectious diarrhea, typhoid fever (enteric fever), uncomplicated cervical and urethral gonorrhea, and inhalational anthrax (post-exposure).
Tương Tác Thuốc :
  • Acenocoumarol The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of acenocoumarol.
  • Aluminium Formation of non-absorbable complexes
  • Aminophylline Ciprofloxacin may increase the effect of aminophylline.
  • Anisindione The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of anisindione.
  • Bendamustine Decreases metabolism, thus INCREASING levels of bendamustine. Decreased conversion of bendamustine to active metabolites. Concurrent administration of Ciproflaxacin or other CYP1A2 inhibitors may also increase the levels of bendamustine into active metabolites.
  • Caffeine Ciprofloxacin may increase the effect and toxicity of caffeine.
  • Calcium Formation of non-absorbable complexes
  • Calcium Acetate Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ciprofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
  • Clozapine Ciprofloxacin may increase clozapine serum levels
  • Cyclosporine Ciprofloxacin may increase the effect and toxicity of cyclosporine.
  • Dicoumarol The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of dicumarol.
  • Dihydroxyaluminium Formation of non-absorbable complexes
  • Duloxetine Ciprofloxacin, a strong CYP1A2 inhibitor, may decrease the metabolism of duloxetine. Monitor for changes in the therapeutic and adverse effects of duloxetine if ciprofloxacin is initiated or discontinued.
  • Dyphylline Ciprofloxacin may increase the effect of dyphylline.
  • Eltrombopag Affects hepatic CYP1A2 metabolism, will increase effect/level of eltrombopag.
  • Ethotoin Decreases the hydantoin effect
  • Foscarnet Increased risk of convulsions
  • Iron Formation of non-absorbable complexes
  • Iron Dextran Formation of non-absorbable complexes
  • Lomitapide The effect of coadminstration of lomipatide with ciproflaxacin, and other moderate CYP3A4 inhibitors (such as aprepitant, amprenavir, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil) is unknown. However, as coadministration is likely to increase serum concentrations of lomipatide, concomitant use is contraindicated.
  • Magnesium Formation of non-absorbable complexes
  • Magnesium oxide Formation of non-absorbable complexes
  • Mephenytoin Decreases the hydantoin effect
  • Methotrexate Ciprofloxacine may decrease the metabolism of methotrexate. Monitor for changes adverse effects of methotrexate if ciprofloxacin is initiated.
  • Oxtriphylline Ciprofloxacin may increase the effect of oxtriphylline.
  • Phenytoin Ciprofloxacin may decrease the therapeutic effect of phenytoin.
  • Procainamide Ciprofloxacin may increase the effect of procainamide.
  • Ramelteon Ciprofloxacin increases levels/toxicity of ramelteon
  • Rasagiline Ciprofloxacin, a strong CYP1A2 inhibitor, may decrease the metabolism of rasagiline. Monitor for changes in the therapeutic and adverse effects of rasagiline if ciprofloxacin is initiated or discontinued.
  • Ropinirole Ciprofloxacin may increase the effect and toxicity of ropinirole.
  • Sevelamer Sevelamer decreases ciprofloxacin bioavailability
  • Sildenafil Ciprofloxacin may increase the serum level of sildenafil.
  • Sucralfate Formation of non-absorbable complexes
  • Tacrine The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ciprofloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ciprofloxacin is initiated, discontinued or if the dose is changed.
  • Theophylline Ciprofloxacin may increase the effect of theophylline.
  • Thiothixene The strong CYP1A2 inhibitor, Ciprofloxacin, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ciprofloxacin is initiated, discontinued or dose changed.
  • Tizanidine Ciprofloxacin inhibits the metabolism and clearance of Tizanidine. Concomitant therapy is contraindicated.
  • Warfarin The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of warfarin.
  • Zinc Formation of non-absorbable complexes
Liều Lượng & Cách Dùng : Ointment - Ophthalmic
Solution - Intravenous
Solution - Ophthalmic
Suspension - Oral
Tablet - Oral
Tablet, extended release - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Bacquinor
  • Công ty :
    Sản phẩm biệt dược : Baycip
  • Công ty :
    Sản phẩm biệt dược : Ciflox
  • Công ty :
    Sản phẩm biệt dược : Cifloxin
  • Công ty : Alcon Canada
    Sản phẩm biệt dược : Ciloxan
  • Công ty :
    Sản phẩm biệt dược : Ciprinol
  • Công ty :
    Sản phẩm biệt dược : Cipro
  • Công ty :
    Sản phẩm biệt dược : Ciprobay
  • Công ty :
    Sản phẩm biệt dược : Ciprocinol
  • Công ty :
    Sản phẩm biệt dược : Ciprodar
  • Công ty :
    Sản phẩm biệt dược : Ciproxan
  • Công ty :
    Sản phẩm biệt dược : Ciproxin
  • Công ty :
    Sản phẩm biệt dược : Flociprin
  • Công ty :
    Sản phẩm biệt dược : Proquin
  • Công ty :
    Sản phẩm biệt dược : Proquin XR
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00537
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=2764
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46504733
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C05349
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00186
ChemSpider
http://www.chemspider.com/Chemical-Structure.2662.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=21690
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/51672-4085-1
PharmGKB
http://www.pharmgkb.org/drug/PA449009
Wikipedia
http://en.wikipedia.org/wiki/Ciprofloxacin
RxList
http://www.rxlist.com/cgi/generic/cipro.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cip1082.shtml
Drugs.com
http://www.drugs.com/cdi/ciprofloxacin-drops.html
... loading
... loading